Palbociclib + Ganitumab In Ewing Sarcoma

Status Completed

Clinical Trial Summary

This research study is designed to study the combination of two drugs, palbociclib and ganitumab, as a potential treatment for Ewing sarcoma. The names of the study drugs involved in this study are: - Palbociclib - Ganitumab

Clinical Trial Description

This research study involves participants taking a medicine that inhibits proteins in cancer cells called CDK4 and CDK6 (palbociclib) in combination with a medicine that inhibits a protein called IGF-1R (ganitumab). This study is designed to see if these drugs are safe when given together and whether they are effective in treating Ewing sarcoma. This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug or drug combination to learn whether the drug(s) works in treating a specific disease. "Investigational" means that the drug or combination is being studied. The U.S. Food and Drug Administration (FDA) has not approved ganitumab as a treatment for any disease. The U.S. Food and Drug Administration (FDA) has not approved palbociclib for this specific disease but it has been approved for another cancer. This research study is: - Testing whether palbociclib and ganitumab are safe when given together and effective in treating Ewing sarcoma. - Testing markers in the blood and in tumor tissue to see if there are certain features of the tumor that may indicate this combination of drugs is effective or not effective ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04129151
Study type	Interventional
Source	Dana-Farber Cancer Institute
Contact
Status	Completed
Phase	Phase 2
Start date	December 5, 2019
Completion date	December 15, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00026780` - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Recruiting	`NCT06094101` - Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)	Phase 1/Phase 2
Recruiting	`NCT06029218` - Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy	N/A
Completed	`NCT00743496` - A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma	Phase 1
Recruiting	`NCT04337177` - Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors	Phase 1
Active, not recruiting	`NCT02945800` - Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma	Phase 2
Recruiting	`NCT06156410` - Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma	Phase 1
Recruiting	`NCT05968768` - To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)	Phase 2
Terminated	`NCT02536183` - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors	Phase 1
Recruiting	`NCT03715933` - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Phase 1
Active, not recruiting	`NCT03220035` - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Completed	`NCT05093322` - A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT02856048` - Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer	Phase 2/Phase 3
Withdrawn	`NCT03880123` - Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma	Phase 1
Completed	`NCT04956198` - Drug Sensitivity and Mutation Profiling
Recruiting	`NCT04791228` - A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors	Phase 2
Recruiting	`NCT06068075` - Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD	N/A
Active, not recruiting	`NCT03709680` - Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05734066` - Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma	Phase 1/Phase 2
Completed	`NCT02044120` - ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma	Phase 1